<DOC>
	<DOCNO>NCT01424891</DOCNO>
	<brief_summary>Lowering LDL cholesterol statins proven associate reduction proinflammatory regulator e.g . activation transcription factor NF-ĸB . Up effect newer cholesterol lower agent ezetemibe respect anti-inflammatory potential less intensively study . Therefore investigator analyze whether equipotent LDL-lowering therapy simvastatin alone combination ezetimibe comparable effect NF-ĸB-activation peripheral blood mononuclear cell ( PBMCs ) patient type 2 diabetes .</brief_summary>
	<brief_title>Effects NF-κB Activity : High Dose Simvastatin Versus Combination Therapy With Ezetimibe</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>35 80 year old type 2 diabetes HbA1c value 6.0 % 9.0 % elevate LDLc value &gt; 100 mg/dl lipid lower treatment within last six month refuse informed consent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>